GlassScriptPhysician profile
Joseph G Herrmann
NPI 1437171998
$3,249.05
in general payments reported to CMS, 2019-2025
32 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $684 · 2020: $399 · 2021: $844 · 2022: $931 · 2023: $267 · 2024: $15.35 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $391.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $952.81 | 2019-2025 | |
| Avion Pharmaceuticals | $371.63 | 2019-2023 | Balcoltra |
| Allergan, INC. | $156.16 | 2019-2020 | |
| Therapeuticsmd, INC. | $148.63 | 2020-2022 | |
| Agile Therapeutics, INC. | $125.56 | 2021-2023 | Twirla |
| Mayne Pharma Commercial LLC | $121.26 | 2021-2022 | |
| Evofem Biosciences, INC. | $117.35 | 2020-2021 | |
| Astellas Pharma US INC | $116.47 | 2022-2023 | Veozah |
| Meditrina | $107.85 | 2021-2022 | |
| Pfizer INC. | $101.72 | 2019-2023 | |
| Novo Nordisk INC | $90.33 | 2019-2023 | Wegovy |
| Myovant Sciences INC. | $81.23 | 2022 | |
| Exeltis, USA INC. | $77.72 | 2020-2024 | Slynd |
| Hologic Sales and Service, LLC | $72.59 | 2022-2023 | Aptima, Thinprep 2000 Processor, Third Wave |
| Biohaven Pharmaceutical Holding Company LTD. | $69.88 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $63.15 | 2021 | |
| Lupin INC. | $61.87 | 2020-2021 | |
| Scynexis, INC. | $48.07 | 2021-2022 | |
| Amgen INC. | $46.56 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $42.83 | 2019-2021 | |
| Axsome Therapeutics, INC. | $42.07 | 2022-2023 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $32.03 | 2019 | |
| Covidien LP | $27.99 | 2020 | |
| Vertical Pharmaceuticals, LLC | $27.99 | 2019 | |
| Mylan Pharmaceuticals INC. | $22.31 | 2022 | |
| Duchesnay USA Incorporated | $22.04 | 2019 | |
| Coopersurgical, INC. | $21.60 | 2023 | Wallach Cryosurgical Equipment |
| Shield Therapeutics INC | $20.65 | 2022 | |
| Sumitomo Pharma America, INC. | $18.57 | 2023 | Myfembree |
| Mission Pharmacal Company | $14.26 | 2020 | |
| Sage Therapeutics, LLC | $13.73 | 2021 | |
| Smith+Nephew, INC. | $12.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Herrmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.